Pfizer hit with patent infringement lawsuit over COVID-19 drug Paxlovid
A US-based biotech is seeking damages for Pfizer’s use of a patented coronavirus 3CL protease inhibitor in its blockbuster drug Paxlovid
Enanta Pharmaceuticals, a clinical-stage biotechnology company that creates novel, small molecule drugs for viral infections and liver diseases, announced this week that it is taking legal action against Pfizer for alleged patent infringement.
Enanta told the court it received the patent for its antiviral medication last week based on applications dating from July 2020. This patent covers a chemical compound that blocks the coronavirus from reproducing. The company said it began human testing for its oral COVID treatment in February, and that the US Food and Drug Administration (FDA) fast-tracked its review in March.
The lawsuit says Paxlovid works in the same way as Enanta's patented antiviral.
Enanta said it was seeking ‘fair compensation for Pfizer’s use of a coronavirus 3CL protease inhibitor claimed in the ‘953 patent’ and clarified that it was not asking the court to block Pfizer from selling Paxlovid. The company said it ‘recognises the importance of Paxlovid’s availability to patients’ and would not seek an injunction.
Paxlovid is an oral antiviral drug, commonly taken by high-risk patients to limit serious complications form COVID-19. It is made up of two generic medications, nirmatrelvir and ritonavir, and was granted an emergency use authorisation by the FDA in December 2021.
Pfizer said recently that it expects to make $22 billion in sales from Paxlovid this year, while analysts predicted sales as high as $26.1 billion.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance